Canakinumab (Ilaris®)Antibody screening - Qualitative ELISA Kit
- SKU:
- HUMB00057
- Product Type:
- ELISA Kit
- ELISA Type:
- Biosimilar ELISA
- Biosimilar ELISA Type:
- Qualitative
- Applications:
- ELISA
- Reactivity:
- Human
- Analytes:
- Canakinumab (Ilaris®)
- Research Area:
- Anti-Inflammatory
Description
Canakinumab (Ilaris®) Antibody screening - Qualitative ELISA Kit
Assay Genie Qualitative Antibodies to Canakinumab ELISA has been especially developed for the qualitative analysis of antibodies to canakinumab in serum and plasma samples. Assay Genie Qualitative Antibodies to Canakinumab ELISA is optimized with Ilaris®
Canakinumab (Ilaris®) Antibody screening - Qualitative ELISA Kit test principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug canakinumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to canakinumab antibodies captured by the drug canakinumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The colour developed is proportional to the amount of canakinumab antibodies in the sample or controls. The results can be evaluated with using cutoff value.
Canakinumab (Ilaris®) Antibody screening - Qualitative ELISA Kit Product Infromation
| Key Information | Description |
Application | Antibody screening - Qualitative |
Required Volume | 10 µl |
Total Time | 140 minutes |
Sample Type | Serum, Plasma |
Number of Assays | 96 |
Detection Limit | + / - ng/mL |
Spike Recovery | - |
Shelf Life (year) | 1 |
Alternative Names | - |
About Canakinumab (Ilaris®) Antibody screening - Qualitative ELISA Kit
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).
In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1β) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1β, and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1β activation. Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra).
Assay Genie ELISA kits can be used for drug level and anti-drug antibodies measurements.
Assay Genie Canakinumab ELISA products:
